Key Performance
More- Earnings Score: N/A
- Momentum Score: 68
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Evaxion A/S announced the promotion of Birgitte Rønø to serve as both Chief Scientific Officer and Chief Operating Officer, reflecting her extensive contributions to the company's operations and scientific expertise. The move is intended to enhance external engagement and strategy execution while strengthening the company's ability to communicate its AI-Immunology™ platform capabilities to partners and investors.
04/27/2026, 8:00 AM • GlobeNewswire
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
Evaxion announced data demonstrating its AI-Immunology platform can identify endogenous retrovirus (ERV)-derived antigens for glioblastoma vaccine design, in collaboration with Duke University. The findings show ERVs as a novel antigen source that could overcome limitations from low mutational burden in brain cancer, with results to be presented at the AACR Annual Meeting in April 2026.
04/17/2026, 3:00 PM • GlobeNewswire
Evaxion has completed the one-year extension of its phase 2 trial for EVX-01, a personalized cancer vaccine for advanced melanoma. The trial demonstrated a 75% Objective Response Rate with 92% of patients still responding at two-year follow-up. Three-year clinical efficacy data is expected in the second half of 2026.
04/07/2026, 8:00 AM • GlobeNewswire
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
Evaxion has developed novel polio vaccine design concepts using its AI-Immunology™ platform in collaboration with the Gates Foundation. The company will present these concepts, along with data from its EVX-V1 cytomegalovirus vaccine program, at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026. The new polio vaccine designs aim to combine the strengths of existing vaccines while addressing their individual shortcomings.
03/30/2026, 8:00 AM • GlobeNewswire
Notice to convene Evaxion’s Annual General Meeting
Evaxion A/S, a clinical-stage TechBio company, announced its Annual General Meeting scheduled for April 16, 2026, at its Copenhagen offices. The company continues developing novel vaccines using its AI-Immunology™ platform for cancer and infectious diseases, with a clinical pipeline of personalized and off-the-shelf vaccine candidates.
03/19/2026, 9:00 AM • GlobeNewswire
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, will report its full year 2025 financial results and provide a business update on March 5, 2026. The company will host a conference call and webcast at 14:30 CET/08:30 EST to present results and discuss its AI-Immunology™ platform development for cancer vaccines, infectious disease vaccines, and newly expanded autoimmune disease applications.
03/02/2026, 8:00 AM • GlobeNewswire
Evaxion expands AI-Immunology™ platform into autoimmune diseases
Evaxion A/S announced expansion of its AI-Immunology platform to include autoimmune diseases as a third disease area alongside cancer and infectious diseases. The company outlined 2026 milestones including biomarker data for EVX-01, autoimmune disease application development, three-year phase 2 efficacy data, and regulatory filings. Cash runway extends to second half of 2027. Additionally, MSD declined to exercise its option on the Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to out-license it to other partners.
01/13/2026, 8:00 AM • GlobeNewswire
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck & Co. has decided not to exercise its option for Evaxion's gonorrhea vaccine candidate EVX-B2 (protein-based version), allowing Evaxion to retain global rights and seek alternative licensing partners. The decision does not impact Evaxion's cash runway extending to mid-2027. Evaxion continues developing an mRNA version with Afrigen Biologics and previously out-licensed EVX-B3 to Merck in September for $7.5 million upfront plus up to $592 million in milestone payments.
12/19/2025, 12:43 PM • Benzinga
Evaxion announce 2026 financial calendar
Evaxion A/S announced its financial calendar for 2026, including key dates for business updates and financial results presentations throughout the year.
11/12/2025, 8:00 AM • GlobeNewswire
Evaxion raises $7.2 million, extending cash runway to second half of 2027
Evaxion raised $7.2 million through share sales and warrant exercises, extending its operational runway into the second half of 2027 and reducing outstanding warrants by 1.0 million.
10/30/2025, 8:00 AM • GlobeNewswire
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
Evaxion A/S has appointed Dr. Helen Tayton-Martin as its new CEO, effective November 24, 2025. She brings extensive biotech experience from Adaptimmune and will lead the company's AI-powered vaccine development strategy.
10/27/2025, 8:00 AM • GlobeNewswire
Evaxion will present new biomarker and immune data for its personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting, highlighting results from an ongoing phase 2 trial combining the vaccine with Merck's KEYTRUDA in advanced melanoma treatment.
10/03/2025, 9:00 AM • GlobeNewswire
The market for untreated metastatic melanoma is poised for strong growth, with over 10 companies driving innovation through advanced immunotherapies, targeted treatments, and combination therapies.
08/26/2025, 1:00 PM • GlobeNewswire
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
Evaxion, a clinical-stage TechBio company developing AI-powered vaccines, will host a conference call and webcast on August 14, 2025, to present its Q2 2025 financial results and provide a business update.
08/11/2025, 8:00 AM • GlobeNewswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.
07/29/2025, 3:46 PM • Benzinga
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.